GLP‑1 Receptor Agonist Use Across Preconception, Pregnancy, and the Postpartum P
GLP-1 RA use in pregnancy remains controversial due to limited human data. This review synthesizes available evidence on risks and benefits across reproductive stages.
Lower Risk of Cardiovascular Events in Patients With Clinical Atherosclerotic Ca
Semaglutide 2.4 mg significantly lowers the risk of heart attacks, strokes, and mortality in ASCVD patients with overweight or obesity. This study highlights its broad benefits beyond diabetes management.
Once-weekly semaglutide versus placebo in patients with alcohol use disorder and
Semaglutide treatment led to a 13.7 percentage point reduction in heavy drinking days compared to placebo in patients with alcohol use disorder and obesity.
Repurposing semaglutide as an adjunctive treatment for cocaine use disorder- pro
Researchers are testing semaglutide as an adjunct to cognitive behavioral therapy for cocaine use disorder. This phase IIa trial aims to evaluate its efficacy and safety in reducing cocaine use and cravings.
Real-World Alcohol Use Disorder Outcomes in PatientsWith Concurrent Metabolic Dy
A recent study shows that GLP-1 receptor agonists are associated with a 45% lower rate of one-year AUD relapse compared to naltrexone in patients with concurrent metabolic dysfunction.
Real-World Cardiovascular Outcomes of ObesityTreatment With Tirzepatide Versus Semaglutide
Tirzepatide significantly reduces new-onset heart failure risk compared to semaglutide in obese, non-diabetic adults over 12 months
New Insights on GLP-1 Receptor Agonist Side Effects from Patient Reports
This analysis focuses on GLP-1 receptor agonist patient-reported side effects gathered from real-world evidence. It highlights emerging safety signals beyond traditional clinical trial data. Clinicians should consider these findings to improve patient…
Comparing Liraglutide and Tirzepatide: Clinical Evidence for Weight Loss
This article presents liraglutide tirzepatide clinical comparison weight loss evidence, highlighting tirzepatide's dual agonist advantage. Tirzepatide achieves greater weight reduction than liraglutide in trials. Understanding these differences supports…
Clinical Evidence and Safety of Semaglutide for Weight Management
Semaglutide chronic weight management is supported by robust clinical evidence demonstrating significant weight loss and metabolic benefits. This GLP-1 receptor agonist is FDA-approved for adults with obesity or overweight with related conditions.…
What a Target Trial Emulation Reveals About GLP-1 Safety in Patients With Opiate Use Disorder
This large target trial emulation evaluated GLP-1 safety in opioid use disorder using national claims data. Investigators found no increased risk across ten gastrointestinal, psychiatric, respiratory, and renal outcomes. The findings provide important…